Literature DB >> 32027394

How do you… decide which platelet bacterial risk mitigation strategy to select for your hospital-based transfusion service?

Wen Lu1, Meghan Delaney2, Willy A Flegel3, Paul Ness4, Nora Ratcliffe5, Darrell J Triulzi6, Mark H Yazer6, Alyssa Ziman7, Nancy M Dunbar8.   

Abstract

The United States Food and Drug Administration Final Guidance for Industry titled, "Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion" provides nine strategies for platelet bacterial risk mitigation. Even if it is assumed all strategies are comparable in terms of safety and efficacy, the decision of which to implement remains challenging. Some additional factors that warrant evaluation before selecting a strategy include the financial impact, process for implementation, logistics upon implementation, institutional acceptance by blood bank staff, administration and clinicians, and effect on platelet availability. To assist with this difficult choice, a panel of transfusion service physicians who have expertise on the topic and have already selected strategies for their transfusion services were recruited to provide varied perspectives. In addition, the use of a decision-making tool that objectively evaluates defined criteria for assessment of the nine strategies is described.
© 2020 AABB.

Entities:  

Mesh:

Year:  2020        PMID: 32027394      PMCID: PMC7131880          DOI: 10.1111/trf.15693

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.337


  18 in total

1.  Financial impact of alternative approaches to reduce bacterial contamination of platelet transfusions.

Authors:  Seema Kacker; Evan M Bloch; Paul M Ness; Eric A Gehrie; Christi E Marshall; Parvez M Lokhandwala; Aaron A R Tobian
Journal:  Transfusion       Date:  2019-01-08       Impact factor: 3.157

2.  The role of pathogen-reduced platelet transfusions on HLA alloimmunization in hemato-oncological patients.

Authors:  Anno Saris; Jean Louis Kerkhoffs; Philip J Norris; S Marieke van Ham; Anja Ten Brinke; Anneke Brand; Pieter F van der Meer; Jaap Jan Zwaginga
Journal:  Transfusion       Date:  2018-11-30       Impact factor: 3.157

3.  Bacterial screening of apheresis platelets with a rapid test: a 113-month single center experience.

Authors:  Kristen N Ruby; Reggie R Thomasson; Zbigniew M Szczepiorkowski; Nancy M Dunbar
Journal:  Transfusion       Date:  2018-04-17       Impact factor: 3.157

Review 4.  Prevention of transfusion-associated graft-versus-host disease with pathogen-reduced platelets with amotosalen and ultraviolet A light: a review.

Authors:  J Cid
Journal:  Vox Sang       Date:  2017-08-18       Impact factor: 2.144

Review 5.  AABB Committee Report: reducing transfusion-transmitted cytomegalovirus infections.

Authors:  Nancy M Heddle; Michael Boeckh; Brenda Grossman; Jessica Jacobson; Steven Kleinman; Aaron A R Tobian; Kathryn Webert; Edward C C Wong; John D Roback
Journal:  Transfusion       Date:  2016-03-10       Impact factor: 3.157

Review 6.  Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation.

Authors:  Heather L Reddy; Anthony D Dayan; Joy Cavagnaro; Shayne Gad; Junzhi Li; Raymond P Goodrich
Journal:  Transfus Med Rev       Date:  2008-04

7.  Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.

Authors:  Jeffrey McCullough; David H Vesole; Richard J Benjamin; Sherrill J Slichter; Alvaro Pineda; Edward Snyder; Edward A Stadtmauer; Ileana Lopez-Plaza; Steven Coutre; Ronald G Strauss; Lawrence T Goodnough; Joy L Fridey; Thomas Raife; Ritchard Cable; Scott Murphy; Frank Howard; Kathryn Davis; Jin-Sying Lin; Peyton Metzel; Laurence Corash; Antonis Koutsoukos; Lily Lin; Donald H Buchholz; Maureen G Conlan
Journal:  Blood       Date:  2004-05-11       Impact factor: 22.113

8.  Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial.

Authors:  Pieter F van der Meer; Paula F Ypma; Nan van Geloven; Joost A van Hilten; Rinie J van Wordragen-Vlaswinkel; Okke Eissen; Jaap J Zwaginga; Michael Trus; Erik A M Beckers; Peter Te Boekhorst; Alan Tinmouth; Yulia Lin; Cyrus Hsia; David Lee; Philip J Norris; Raymond P Goodrich; Anneke Brand; Tor Hervig; Nancy M Heddle; Johanna G van der Bom; Jean-Louis H Kerkhoffs
Journal:  Blood       Date:  2018-05-17       Impact factor: 22.113

9.  Sepsis Attributed to Bacterial Contamination of Platelets Associated with a Potential Common Source - Multiple States, 2018.

Authors:  Sydney A Jones; Jefferson M Jones; Vivian Leung; Allyn K Nakashima; Kelly F Oakeson; Amanda R Smith; Robert Hunter; Janice J Kim; Melissa Cumming; Eileen McHale; Pampee P Young; Joy L Fridey; Walter E Kelley; Susan L Stramer; Stephen J Wagner; F Bernadette West; Ross Herron; Edward Snyder; Jeanne E Hendrickson; David R Peaper; Adi V Gundlapalli; Charles Langelier; Steve Miller; Ashok Nambiar; Morvarid Moayeri; Jack Kamm; Heather Moulton-Meissner; Pallavi Annambhotla; Paige Gable; Gillian A McAllister; Erin Breaker; Erisa Sula; Alison Laufer Halpin; Sridhar V Basavaraju
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-06-14       Impact factor: 17.586

10.  Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial.

Authors:  Frédéric Garban; Audrey Guyard; Helene Labussière; Claude-Eric Bulabois; Tony Marchand; Christiane Mounier; Denis Caillot; Jacques-Olivier Bay; Valérie Coiteux; Aline Schmidt-Tanguy; Catherine Le Niger; Christine Robin; Patrick Ladaique; Simona Lapusan; Eric Deconinck; Carole Rolland; Alison M Foote; Anne François; Chantal Jacquot; René Tardivel; Pierre Tiberghien; Jean-Luc Bosson
Journal:  JAMA Oncol       Date:  2018-04-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.